Zydus Lifesciences’ novel COVID-19 vaccine, ZyCoV-D has received Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) as a two dose vaccine. With this approval, the vaccine will now be administered on day 0 and day 28. Earlier, the vaccine was approved in a three dose regimen to be administered on day 0, day 28 and day 56.
Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.